Global drug major Eli Lilly has signed an agreement with Cipla allowing the Indian company to sell its popular weight-loss drug tirzepatide under a separate brand in the country, the two companies said on Thursday. Under the agreement, Lilly will manufacture and supply the drug to Cipla which will market it under the brand name Yurpeak.

Yurpeak will be available to Indian patients as a once-weekly pre-filled injector pen, same as Lilly’s Mounjaro Kwikpen, and at the same price. Each pen contains four fixed doses, and it will be available in six dose strengths, allowing healthcare professionals to personalise treatment plans to better suit individual patient needs.

The arrangement will allow broader access to the drug across the country beyond cities where Lilly already has an establish

See Full Page